25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

PYC (PYC Therapeutics Ltd) Stock Analysis
Buy, Hold or Sell?

Let's analyze PYC Therapeutics Ltd together

I guess you are interested in PYC Therapeutics Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – PYC Therapeutics Ltd’s Financial Insights
  • 📈 Technical Analysis (TA) – PYC Therapeutics Ltd’s Price Targets

I'm going to help you getting a better view of PYC Therapeutics Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about PYC Therapeutics Ltd

I send you an email if I find something interesting about PYC Therapeutics Ltd.

1. Quick Overview

1.1. Quick analysis of PYC Therapeutics Ltd (30 sec.)










1.2. What can you expect buying and holding a share of PYC Therapeutics Ltd? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
30.0%

What is your share worth?

Current worth
A$0.29
Expected worth in 1 year
A$1.38
How sure are you?
70.0%

+ What do you gain per year?

Total Gains per Share
A$1.08
Return On Investment
121.1%

For what price can you sell your share?

Current Price per Share
A$0.90
Expected price per share
A$0.7666 - A$0.95
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of PYC Therapeutics Ltd (5 min.)




Live pricePrice per Share (EOD)
A$0.90
Intrinsic Value Per Share
A$-1.29 - A$-0.51
Total Value Per Share
A$-1.00 - A$-0.22

2.2. Growth of PYC Therapeutics Ltd (5 min.)




Is PYC Therapeutics Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$113.1m$53.9m$59.2m52.3%

How much money is PYC Therapeutics Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$33.4m-$25.1m-$8.3m-25.0%
Net Profit Margin0.0%-171.0%--

How much money comes from the company's main activities?

2.3. Financial Health of PYC Therapeutics Ltd (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#308 / 853

Most Revenue
#741 / 853

Most Profit
#704 / 853

Most Efficient
#179 / 853
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of PYC Therapeutics Ltd?

Welcome investor! PYC Therapeutics Ltd's management wants to use your money to grow the business. In return you get a share of PYC Therapeutics Ltd.

First you should know what it really means to hold a share of PYC Therapeutics Ltd. And how you can make/lose money.

Speculation

The Price per Share of PYC Therapeutics Ltd is A$0.895. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of PYC Therapeutics Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in PYC Therapeutics Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.29. Based on the TTM, the Book Value Change Per Share is A$0.27 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of PYC Therapeutics Ltd.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.06-6.4%-0.06-6.4%-0.01-0.7%-0.02-2.5%-0.02-1.7%-0.01-0.9%
Usd Book Value Change Per Share0.1820.1%0.1820.1%0.010.9%0.066.9%0.044.2%0.022.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.1%0.000.2%0.000.2%
Usd Total Gains Per Share0.1820.1%0.1820.1%0.010.9%0.067.0%0.044.4%0.022.3%
Usd Price Per Share0.86-0.86-0.08-0.33-0.23-0.13-
Price to Earnings Ratio-15.01--15.01--12.52--11.84--15.58--20.34-
Price-to-Total Gains Ratio4.78-4.78-10.14--31.34--19.83--4.54-
Price to Book Ratio4.44-4.44-5.83-5.56-6.17-10.36-
Price-to-Total Gains Ratio4.78-4.78-10.14--31.34--19.83--4.54-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.595712
Number of shares1678
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.180.04
Usd Total Gains Per Share0.180.04
Gains per Quarter (1678 shares)302.5566.01
Gains per Year (1678 shares)1,210.18264.03
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101210120013251254
202420241026502518
303631362040752782
40484148305310031046
50605160406612541310
60726172507915051574
70847184609317561838
809681967010620062102
90108921088011922572366
100121021209013225082630

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.021.01.00.0%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%3.02.00.060.0%7.03.00.070.0%13.09.00.059.1%
Dividend per Share0.00.01.00.0%1.00.02.033.3%2.00.03.040.0%3.00.07.030.0%3.00.019.013.6%
Total Gains per Share1.00.00.0100.0%2.01.00.066.7%3.02.00.060.0%7.03.00.070.0%13.09.00.059.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of PYC Therapeutics Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.2710.2710%0.012+2188%0.093+191%0.056+383%0.029+830%
Book Value Per Share--0.2910.2910%0.021+1315%0.107+173%0.070+316%0.037+684%
Current Ratio--14.41314.4130%9.401+53%9.202+57%10.451+38%11.762+23%
Debt To Asset Ratio--0.0720.0720%0.112-35%0.140-48%0.120-40%0.156-54%
Debt To Equity Ratio--0.0780.0780%0.127-38%0.173-55%0.145-46%0.233-66%
Dividend Per Share----0%-0%0.001-100%0.003-100%0.002-100%
Enterprise Value--742051453.160742051453.1600%528999763.760+40%486611032.861+52%445146599.089+67%284359334.046+161%
Eps---0.086-0.0860%-0.010-89%-0.034-60%-0.023-74%-0.012-86%
Free Cash Flow Per Share---0.090-0.0900%-0.010-89%-0.036-60%-0.024-74%-0.013-86%
Free Cash Flow To Equity Per Share--0.1480.1480%0.013+1033%0.052+183%0.032+367%0.017+783%
Gross Profit Margin--1.0001.0000%1.0000%1.014-1%1.029-3%1.156-13%
Intrinsic Value_10Y_max---0.509----------
Intrinsic Value_10Y_min---1.289----------
Intrinsic Value_1Y_max---0.021----------
Intrinsic Value_1Y_min---0.060----------
Intrinsic Value_3Y_max---0.086----------
Intrinsic Value_3Y_min---0.241----------
Intrinsic Value_5Y_max---0.179----------
Intrinsic Value_5Y_min---0.488----------
Market Cap522017728.640-45%755322280.160755322280.1600%472309274.760+60%469855067.195+61%420803765.289+79%267655804.846+182%
Net Profit Margin----0%-1.7100%-1.0510%-1.9590%-2018.3470%
Operating Margin----0%-1.7760%-1.4170%-2.6370%-3441.2580%
Operating Ratio----0%2.810-100%1.763-100%2.854-100%3416.149-100%
Pb Ratio3.071-45%4.4434.4430%5.827-24%5.555-20%6.174-28%10.358-57%
Pe Ratio-10.377+31%-15.015-15.0150%-12.520-17%-11.839-21%-15.585+4%-20.337+35%
Price Per Share0.895-45%1.2951.2950%0.120+979%0.490+164%0.338+283%0.192+575%
Price To Free Cash Flow Ratio-9.936+31%-14.377-14.3770%-12.143-16%-11.274-22%-16.487+15%-21.396+49%
Price To Total Gains Ratio3.304-45%4.7814.7810%10.136-53%-31.343+756%-19.831+515%-4.538+195%
Quick Ratio----0%9.319-100%4.368-100%9.548-100%14.993-100%
Return On Assets---0.274-0.2740%-0.413+51%-0.434+58%-0.383+39%-0.565+106%
Return On Equity---0.297-0.2970%-0.469+58%-0.529+78%-0.455+53%-0.858+189%
Total Gains Per Share--0.2710.2710%0.012+2188%0.094+188%0.059+358%0.031+762%
Usd Book Value--113157605.018113157605.0180%53950054.912+110%62013017.941+82%49737938.166+128%28385431.660+299%
Usd Book Value Change Per Share--0.1800.1800%0.008+2188%0.062+191%0.037+383%0.019+830%
Usd Book Value Per Share--0.1940.1940%0.014+1315%0.071+173%0.047+316%0.025+684%
Usd Dividend Per Share----0%-0%0.001-100%0.002-100%0.002-100%
Usd Enterprise Value--493909447.223493909447.2230%352102242.759+40%323888303.473+52%296289576.354+67%189269572.741+161%
Usd Eps---0.057-0.0570%-0.006-89%-0.023-60%-0.015-74%-0.008-86%
Usd Free Cash Flow---34967613.491-34967613.4910%-25888874.752-26%-25812816.418-26%-20087190.323-43%-11603527.603-67%
Usd Free Cash Flow Per Share---0.060-0.0600%-0.007-89%-0.024-60%-0.016-74%-0.009-86%
Usd Free Cash Flow To Equity Per Share--0.0980.0980%0.009+1033%0.035+183%0.021+367%0.011+783%
Usd Market Cap347455000.183-45%502742509.674502742509.6740%314369053.280+60%312735532.725+61%280086986.177+79%178151703.706+182%
Usd Price Per Share0.596-45%0.8620.8620%0.080+979%0.326+164%0.225+283%0.128+575%
Usd Profit---33482794.342-33482794.3420%-25110033.562-25%-24587058.773-27%-18962920.038-43%-11096570.900-67%
Usd Revenue----0%14682679.398-100%8401107.797-100%7585544.878-100%4139431.895-100%
Usd Total Gains Per Share--0.1800.1800%0.008+2188%0.063+188%0.039+358%0.021+762%
 EOD+2 -6MRQTTM+0 -0YOY+23 -103Y+24 -125Y+22 -1410Y+22 -14

3.3 Fundamental Score

Let's check the fundamental score of PYC Therapeutics Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-10.377
Price to Book Ratio (EOD)Between0-13.071
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than114.413
Debt to Asset Ratio (MRQ)Less than10.072
Debt to Equity Ratio (MRQ)Less than10.078
Return on Equity (MRQ)Greater than0.15-0.297
Return on Assets (MRQ)Greater than0.05-0.274
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of PYC Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5022.914
Ma 20Greater thanMa 501.219
Ma 50Greater thanMa 1001.274
Ma 100Greater thanMa 2001.260
OpenGreater thanClose0.890
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About PYC Therapeutics Ltd

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program which is Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for the treatment of blinding eye disease named Autosomal Dominant Optic Atrophy, which is in clinical studies; PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder named Phelan-McDermid Syndrome, which is in pre-clinical studies; and PYC-003 to treat autosomal dominant polycystic kidney disease, which is in early-stage clinical trials. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.

Fundamental data was last updated by Penke on 2025-09-16 21:29:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit PYC Therapeutics Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare PYC Therapeutics Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of PYC Therapeutics Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-171.0%+171.0%
TTM-5Y-195.9%+195.9%
5Y-195.9%10Y-201,834.7%+201,638.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--85.5%+85.5%
TTM--171.0%+171.0%
YOY-171.0%-210.0%+39.0%
3Y-105.1%-289.9%+184.8%
5Y-195.9%-381.1%+185.2%
10Y-201,834.7%-520.3%-201,314.4%
4.3.1.2. Return on Assets

Shows how efficient PYC Therapeutics Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare PYC Therapeutics Ltd to the Biotechnology industry mean.
  • -27.4% Return on Assets means that PYC Therapeutics Ltd generated $-0.27 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of PYC Therapeutics Ltd:

  • The MRQ is -27.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -27.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-27.4%TTM-27.4%0.0%
TTM-27.4%YOY-41.3%+13.9%
TTM-27.4%5Y-38.3%+10.8%
5Y-38.3%10Y-56.5%+18.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-27.4%-11.9%-15.5%
TTM-27.4%-11.9%-15.5%
YOY-41.3%-11.2%-30.1%
3Y-43.4%-12.0%-31.4%
5Y-38.3%-11.7%-26.6%
10Y-56.5%-13.8%-42.7%
4.3.1.3. Return on Equity

Shows how efficient PYC Therapeutics Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare PYC Therapeutics Ltd to the Biotechnology industry mean.
  • -29.7% Return on Equity means PYC Therapeutics Ltd generated $-0.30 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of PYC Therapeutics Ltd:

  • The MRQ is -29.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -29.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-29.7%TTM-29.7%0.0%
TTM-29.7%YOY-46.9%+17.2%
TTM-29.7%5Y-45.5%+15.8%
5Y-45.5%10Y-85.8%+40.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-29.7%-14.2%-15.5%
TTM-29.7%-15.2%-14.5%
YOY-46.9%-15.3%-31.6%
3Y-52.9%-16.9%-36.0%
5Y-45.5%-17.5%-28.0%
10Y-85.8%-19.6%-66.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of PYC Therapeutics Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient PYC Therapeutics Ltd is operating .

  • Measures how much profit PYC Therapeutics Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare PYC Therapeutics Ltd to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of PYC Therapeutics Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-177.6%+177.6%
TTM-5Y-263.7%+263.7%
5Y-263.7%10Y-344,125.8%+343,862.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--154.1%+154.1%
TTM--280.2%+280.2%
YOY-177.6%-268.7%+91.1%
3Y-141.7%-281.5%+139.8%
5Y-263.7%-350.8%+87.1%
10Y-344,125.8%-530.7%-343,595.1%
4.3.2.2. Operating Ratio

Measures how efficient PYC Therapeutics Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of PYC Therapeutics Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY2.810-2.810
TTM-5Y2.854-2.854
5Y2.85410Y3,416.149-3,413.294
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.952-1.952
TTM-2.974-2.974
YOY2.8103.047-0.237
3Y1.7633.835-2.072
5Y2.8544.924-2.070
10Y3,416.1496.864+3,409.285
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of PYC Therapeutics Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if PYC Therapeutics Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 14.41 means the company has $14.41 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of PYC Therapeutics Ltd:

  • The MRQ is 14.413. The company is very able to pay all its short-term debts. +2
  • The TTM is 14.413. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ14.413TTM14.4130.000
TTM14.413YOY9.401+5.012
TTM14.4135Y10.451+3.962
5Y10.45110Y11.762-1.311
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.4133.480+10.933
TTM14.4133.790+10.623
YOY9.4014.104+5.297
3Y9.2024.609+4.593
5Y10.4515.764+4.687
10Y11.7626.154+5.608
4.4.3.2. Quick Ratio

Measures if PYC Therapeutics Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare PYC Therapeutics Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off $0.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of PYC Therapeutics Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY9.319-9.319
TTM-5Y9.548-9.548
5Y9.54810Y14.993-5.445
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.938-2.938
TTM-3.291-3.291
YOY9.3193.928+5.391
3Y4.3684.393-0.025
5Y9.5485.837+3.711
10Y14.9936.549+8.444
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of PYC Therapeutics Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of PYC Therapeutics Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare PYC Therapeutics Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.07 means that PYC Therapeutics Ltd assets are financed with 7.2% credit (debt) and the remaining percentage (100% - 7.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of PYC Therapeutics Ltd:

  • The MRQ is 0.072. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.072. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.072TTM0.0720.000
TTM0.072YOY0.112-0.039
TTM0.0725Y0.120-0.048
5Y0.12010Y0.156-0.036
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0720.339-0.267
TTM0.0720.359-0.287
YOY0.1120.334-0.222
3Y0.1400.341-0.201
5Y0.1200.349-0.229
10Y0.1560.379-0.223
4.5.4.2. Debt to Equity Ratio

Measures if PYC Therapeutics Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare PYC Therapeutics Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 7.8% means that company has $0.08 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of PYC Therapeutics Ltd:

  • The MRQ is 0.078. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.078. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.078TTM0.0780.000
TTM0.078YOY0.127-0.048
TTM0.0785Y0.145-0.067
5Y0.14510Y0.233-0.088
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0780.391-0.313
TTM0.0780.436-0.358
YOY0.1270.436-0.309
3Y0.1730.461-0.288
5Y0.1450.461-0.316
10Y0.2330.514-0.281
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings PYC Therapeutics Ltd generates.

  • Above 15 is considered overpriced but always compare PYC Therapeutics Ltd to the Biotechnology industry mean.
  • A PE ratio of -15.01 means the investor is paying $-15.01 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of PYC Therapeutics Ltd:

  • The EOD is -10.377. Based on the earnings, the company is expensive. -2
  • The MRQ is -15.015. Based on the earnings, the company is expensive. -2
  • The TTM is -15.015. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-10.377MRQ-15.015+4.638
MRQ-15.015TTM-15.0150.000
TTM-15.015YOY-12.520-2.495
TTM-15.0155Y-15.585+0.570
5Y-15.58510Y-20.337+4.752
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-10.377-2.539-7.838
MRQ-15.015-2.361-12.654
TTM-15.015-2.657-12.358
YOY-12.520-3.749-8.771
3Y-11.839-3.883-7.956
5Y-15.585-6.353-9.232
10Y-20.337-7.102-13.235
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of PYC Therapeutics Ltd:

  • The EOD is -9.936. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -14.377. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -14.377. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.936MRQ-14.377+4.441
MRQ-14.377TTM-14.3770.000
TTM-14.377YOY-12.143-2.234
TTM-14.3775Y-16.487+2.110
5Y-16.48710Y-21.396+4.909
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.936-3.411-6.525
MRQ-14.377-2.951-11.426
TTM-14.377-3.614-10.763
YOY-12.143-4.421-7.722
3Y-11.274-5.258-6.016
5Y-16.487-8.587-7.900
10Y-21.396-9.639-11.757
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of PYC Therapeutics Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.44 means the investor is paying $4.44 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of PYC Therapeutics Ltd:

  • The EOD is 3.071. Based on the equity, the company is fair priced.
  • The MRQ is 4.443. Based on the equity, the company is fair priced.
  • The TTM is 4.443. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.071MRQ4.443-1.372
MRQ4.443TTM4.4430.000
TTM4.443YOY5.827-1.384
TTM4.4435Y6.174-1.731
5Y6.17410Y10.358-4.183
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.0712.206+0.865
MRQ4.4432.027+2.416
TTM4.4432.194+2.249
YOY5.8272.425+3.402
3Y5.5552.571+2.984
5Y6.1743.805+2.369
10Y10.3584.462+5.896
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of PYC Therapeutics Ltd.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2021-06-302022-06-302023-06-302024-06-302025-06-30
Total Other Income Expense Net -2,9432,934-8-15,724-15,732-1,081-16,81339,10322,290



5.2. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets183,279
Total Liabilities13,271
Total Stockholder Equity169,574
 As reported
Total Liabilities 13,271
Total Stockholder Equity+ 169,574
Total Assets = 183,279

Assets

Total Assets183,279
Total Current Assets177,526
Long-term Assets5,753
Total Current Assets
Cash And Cash Equivalents 153,050
Other Current Assets 408
Total Current Assets  (as reported)177,526
Total Current Assets  (calculated)153,458
+/- 24,068
Long-term Assets
Property Plant Equipment 1,903
Intangible Assets 3,850
Long-term Assets  (as reported)5,753
Long-term Assets  (calculated)5,753
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities12,317
Long-term Liabilities954
Total Stockholder Equity169,574
Total Current Liabilities
Accounts payable 8,753
Total Current Liabilities  (as reported)12,317
Total Current Liabilities  (calculated)8,753
+/- 3,564
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,024
Long-term Liabilities  (as reported)954
Long-term Liabilities  (calculated)1,024
+/- 70
Total Stockholder Equity
Total Stockholder Equity (as reported)169,574
Total Stockholder Equity (calculated)0
+/- 169,574
Other
Capital Stock369,589
Common Stock Shares Outstanding 583,260
Net Invested Capital 169,574
Net Working Capital 165,209
Property Plant and Equipment Gross 6,832



5.3. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-30
> Total Assets 
1,174
6,084
2,832
3,534
3,519
3,487
1,570
5,661
3,495
2,262
4,524
1,786
7,266
10,348
3,419
6,701
31,546
57,941
45,352
37,166
91,239
183,279
183,27991,23937,16645,35257,94131,5466,7013,41910,3487,2661,7864,5242,2623,4955,6611,5703,4873,5193,5342,8326,0841,174
   > Total Current Assets 
0
5,578
2,758
3,419
3,323
3,414
1,405
5,375
3,016
1,926
4,194
1,623
7,199
10,132
3,276
6,218
25,561
51,781
39,249
31,873
85,615
177,526
177,52685,61531,87339,24951,78125,5616,2183,27610,1327,1991,6234,1941,9263,0165,3751,4053,4143,3233,4192,7585,5780
       Cash And Cash Equivalents 
791
5,505
2,639
3,369
3,232
3,073
1,281
5,199
2,779
1,807
4,022
1,476
7,074
9,940
3,147
1,662
7,242
18,435
29,110
15,572
66,875
153,050
153,05066,87515,57229,11018,4357,2421,6623,1479,9407,0741,4764,0221,8072,7795,1991,2813,0733,2323,3692,6395,505791
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,520
18,186
33,067
0
0
0
0
000033,06718,1864,520000000000000000
       Net Receivables 
38
50
11
30
60
342
124
113
235
119
172
119
126
192
18
11
83
186
10,071
16,252
17,996
0
017,99616,25210,0711868311181921261191721192351131243426030115038
       Other Current Assets 
0
22
108
21
31
0
0
62
0
119
172
28
126
192
110
26
50
93
68
50
744
408
408744506893502611019212628172119062003121108220
   > Long-term Assets 
0
507
74
115
196
73
165
287
479
337
330
163
67
216
143
483
5,985
6,160
6,103
5,293
5,624
5,753
5,7535,6245,2936,1036,1605,9854831432166716333033747928716573196115745070
       Property Plant Equipment 
4
40
74
115
196
73
165
287
479
337
330
163
67
216
143
483
1,135
1,486
1,629
1,043
1,574
1,903
1,9031,5741,0431,6291,4861,135483143216671633303374792871657319611574404
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
300
0
0
0
0
0
000003000000000000000000
       Intangible Assets 
340
466
0
0
0
0
0
0
0
0
0
0
0
0
0
4,850
4,850
4,650
4,450
4,250
4,050
3,850
3,8504,0504,2504,4504,6504,8504,8500000000000000466340
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
24
24
0
0
0
000242400000000000000000
> Total Liabilities 
628
304
718
1,337
824
1,576
2,007
1,308
801
1,068
805
824
1,436
1,489
1,772
402
1,351
4,017
5,149
8,723
10,184
13,271
13,27110,1848,7235,1494,0171,3514021,7721,4891,4368248051,0688011,3082,0071,5768241,337718304628
   > Total Current Liabilities 
628
304
718
1,326
814
535
1,982
1,259
777
1,049
800
824
1,436
1,489
1,772
402
706
3,297
4,388
8,406
9,107
12,317
12,3179,1078,4064,3883,2977064021,7721,4891,4368248001,0497771,2591,9825358141,326718304628
       Short-term Debt 
0
0
13
10
7
0
1,100
0
0
0
0
0
0
0
0
153
153
188
260
178
310
0
0310178260188153153000000001,10007101300
       Accounts payable 
72
17
221
579
260
330
561
543
367
718
411
444
1,057
1,446
1,684
194
97
2,346
2,574
4,919
7,527
8,753
8,7537,5274,9192,5742,346971941,6841,4461,0574444117183675435613302605792211772
       Other Current Liabilities 
3
225
339
498
546
205
45
716
410
331
389
379
379
43
88
151
455
763
1,554
3,309
1,271
0
01,2713,3091,5547634551518843379379389331410716452055464983392253
   > Long-term Liabilities 
0
0
0
11
10
1,041
25
50
25
18
6
0
0
0
0
645
645
720
762
318
1,077
954
9541,07731876272064564500006182550251,0411011000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
645
543
684
138
803
0
08031386845436450000000000000000
       Other Liabilities 
0
0
0
11
10
13
25
50
25
18
6
0
0
0
0
0
0
177
78
180
0
0
0018078177000000618255025131011000
> Total Stockholder Equity
546
5,781
2,114
2,197
2,695
1,911
-437
4,353
2,694
1,195
3,719
962
5,830
8,859
1,647
6,299
28,453
53,044
39,352
27,750
80,496
169,574
169,57480,49627,75039,35253,04428,4536,2991,6478,8595,8309623,7191,1952,6944,353-4371,9112,6952,1972,1145,781546
   Common Stock
899
7,721
7,820
11,710
16,676
20,093
21,973
30,367
32,456
34,056
39,666
39,666
48,456
53,209
53,334
61,951
87,207
125,991
125,991
140,087
230,576
0
0230,576140,087125,991125,99187,20761,95153,33453,20948,45639,66639,66634,05632,45630,36721,97320,09316,67611,7107,8207,721899
   Retained Earnings Total Equity0000000000000000000000
   Accumulated Other Comprehensive Income 
0
-7
283
-49
-98
671
1,015
1,016
1,174
1,514
545
780
837
1,064
1,161
1,276
4,996
8,570
8,741
5,832
5,815
0
05,8155,8328,7418,5704,9961,2761,1611,0648377805451,5141,1741,0161,015671-98-49283-70
   Capital Surplus 0000000000000000000000
   Treasury Stock0000000000000000000000
   Other Stockholders Equity 
0
7
0
49
98
0
0
0
0
0
545
780
837
1,064
1,161
1,276
-23,457
-44,474
-30,611
-21,918
0
0
00-21,918-30,611-44,474-23,4571,2761,1611,064837780545000009849070



5.4. Balance Sheets

Currency in AUD. All numbers in thousands.




5.5. Cash Flows

Currency in AUD. All numbers in thousands.




5.6. Income Statements

Currency in AUD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2025-06-30. Currency in AUD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-0
Operating Income-75,9180
 
Operating Expense (+$)
Research Development70,052
Selling General Administrative4,210
Selling And Marketing Expenses0
Operating Expense074,262
 
Net Interest Income (+$)
Interest Income2,677
Interest Expense-62
Other Finance Cost-0
Net Interest Income2,615
 
Pretax Income (+$)
Operating Income-75,918
Net Interest Income2,615
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-51,013-98,208
EBIT - interestExpense = -62
-50,305
-50,242
Interest Expense62
Earnings Before Interest and Taxes (EBIT)0-50,951
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-51,013
Tax Provision-0
Net Income From Continuing Ops-51,013-51,013
Net Income-50,305
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net22,290-2,615
 

Technical Analysis of PYC Therapeutics Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of PYC Therapeutics Ltd. The general trend of PYC Therapeutics Ltd is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine PYC Therapeutics Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. PYC Therapeutics Ltd Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of PYC Therapeutics Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.8951170212766 < 0.93485473684211 < 0.95.

The bearish price targets are: 0.86390373044525 > 0.7956 > 0.7666.

Know someone who trades $PYC? Share this with them.👇

PYC Therapeutics Ltd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of PYC Therapeutics Ltd. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

PYC Therapeutics Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of PYC Therapeutics Ltd. The current macd is -0.06905759.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the PYC Therapeutics Ltd price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for PYC Therapeutics Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the PYC Therapeutics Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
PYC Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) ChartPYC Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of PYC Therapeutics Ltd. The current adx is 31.49.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell PYC Therapeutics Ltd shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
PYC Therapeutics Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of PYC Therapeutics Ltd. The current sar is 1.25987965.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
PYC Therapeutics Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of PYC Therapeutics Ltd. The current rsi is 22.91. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 2/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending up: The RSI is trending up. +1
PYC Therapeutics Ltd Daily Relative Strength Index (RSI) ChartPYC Therapeutics Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of PYC Therapeutics Ltd. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the PYC Therapeutics Ltd price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
PYC Therapeutics Ltd Daily Stochastic Oscillator ChartPYC Therapeutics Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of PYC Therapeutics Ltd. The current cci is -332.67030264.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
PYC Therapeutics Ltd Daily Commodity Channel Index (CCI) ChartPYC Therapeutics Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of PYC Therapeutics Ltd. The current cmo is -64.34343409.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
PYC Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) ChartPYC Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of PYC Therapeutics Ltd. The current willr is -89.72972973.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
PYC Therapeutics Ltd Daily Williams %R ChartPYC Therapeutics Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of PYC Therapeutics Ltd.

PYC Therapeutics Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of PYC Therapeutics Ltd. The current atr is 0.07605727.

PYC Therapeutics Ltd Daily Average True Range (ATR) ChartPYC Therapeutics Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of PYC Therapeutics Ltd. The current obv is -5,387,651.

PYC Therapeutics Ltd Daily On-Balance Volume (OBV) ChartPYC Therapeutics Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of PYC Therapeutics Ltd. The current mfi is 24.00.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
PYC Therapeutics Ltd Daily Money Flow Index (MFI) ChartPYC Therapeutics Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for PYC Therapeutics Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-05-02STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-05STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-09MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-13MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-16MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-18STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-06-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-30STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-07-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-07-16MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-07-21STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-31STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-08-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-08-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-08-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-09-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-09-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-09-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

PYC Therapeutics Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of PYC Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5022.914
Ma 20Greater thanMa 501.219
Ma 50Greater thanMa 1001.274
Ma 100Greater thanMa 2001.260
OpenGreater thanClose0.890
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of PYC Therapeutics Ltd with someone you think should read this too:
  • Are you bullish or bearish on PYC Therapeutics Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about PYC Therapeutics Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about PYC Therapeutics Ltd

I send you an email if I find something interesting about PYC Therapeutics Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about PYC Therapeutics Ltd.

Receive notifications about PYC Therapeutics Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.